➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
AstraZeneca
Baxter
Johnson and Johnson
Dow

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FLORTAUCIPIR F-18

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Flortaucipir F-18

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03040713 Flortaucipir PET Imaging in Subjects With FTD Recruiting Avid Radiopharmaceuticals Phase 1 2017-04-11 This study is designed to assess the usefulness of 18F-AV-1451 in Positron Emission Tomography imaging for subjects diagnosed with Frontotemporal Dementia.
NCT03052972 Flortaucipir 18F PET Imaging in BIOCARD Study Recruiting Avid Radiopharmaceuticals Phase 1 2017-03-23 This study is designed to assess the imaging characteristics of Flortaucipir (18F-AV-1451) in subjects who participated in the Biomarkers of Cognitive Decline Among Normal Individuals (BIOCARD) study at Johns Hopkins University.
NCT03322462 Tau Screening Study in Patients With Early Symptomatic AD Not yet recruiting Avid Radiopharmaceuticals Phase 2 2017-10-01 This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron Emission Tomography (PET) scan.
NCT03467477 Tau Screening Study in Subjects With Early Symptomatic AD Recruiting Avid Radiopharmaceuticals Phase 2 2018-03-08 This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron Emission Tomography (PET) scan.
NCT03901092 A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 PET Scan Interpretation Enrolling by invitation Avid Radiopharmaceuticals Phase 3 2019-03-27 This study will evaluate the performance of physician readers trained to read flortaucipir-PET (positron emission tomography) scans.
NCT03901105 Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease Enrolling by invitation Avid Radiopharmaceuticals Phase 3 2019-03-28 This study will evaluate whether visual interpretation of flortaucipir-PET (positron emission tomography) scans, examining patterns of tracer uptake at baseline, can predict the rate of clinically-meaningful cognitive decline due to AD after 18 months. All scans are acquired from cohorts of a previously completed study, I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Flortaucipir F-18

Condition Name

Condition Name for Flortaucipir F-18
Intervention Trials
Alzheimer Disease 7
Cognitive Decline 2
Mild Cognitive Impairment 1
Frontotemporal Dementia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Flortaucipir F-18
Intervention Trials
Alzheimer Disease 7
Cognitive Dysfunction 3
Dementia 2
Pick Disease of the Brain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Flortaucipir F-18

Trials by Country

Trials by Country for Flortaucipir F-18
Location Trials
United States 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Flortaucipir F-18
Location Trials
California 4
Pennsylvania 2
Florida 2
Rhode Island 1
Kansas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Flortaucipir F-18

Clinical Trial Phase

Clinical Trial Phase for Flortaucipir F-18
Clinical Trial Phase Trials
Phase 3 2
Phase 2 3
Phase 1 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Flortaucipir F-18
Clinical Trial Phase Trials
Recruiting 3
Completed 2
Enrolling by invitation 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Flortaucipir F-18

Sponsor Name

Sponsor Name for Flortaucipir F-18
Sponsor Trials
Avid Radiopharmaceuticals 8
Neil M Rofsky, MD, MHA 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Flortaucipir F-18
Sponsor Trials
Industry 8
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Moodys
Medtronic
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.